# US 2026/0060982 A1 · Use of btk inhibitor and single-dose drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060982 A1
- Document ID: US20260060982A1
- Status: Published application
- Kind: A1
- Application number: 19/382,302
- Filed: 2025-11-07
- Published: 2026-03-05
- Earliest claimed: 2023-05-12
- Assignees: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- Applicants: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- Inventors: Jun YANG; Shengji ZHU; Hongna SUN; Jinping LI; Mingwei SU; Jie ZHU; Ling CAI; Zhenyu HE; Sheng CHEN; Qing XU; Xuejun ZHANG; Lie LI
- Web page: https://patentgrep.com/patent/US20260060982A1

## CPC

- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and/or preventing an immune system disease.

## Claims

### Claim 1

A method for treating and/or preventing an immune system disease, the method comprising:
administering to a subject a pharmaceutically acceptable amount of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I):

### Claim 2 (depends on 1)

The method according to claim 1, wherein the immune system disease comprises an autoimmune disease and/or a skin allergy disorder.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the immune system disease comprises rheumatoid arthritis, urticaria, skin inflammation, and/or eczema.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable amount of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) ranges from about 5 mg to 800 mg.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable amount of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) ranges from about 10 mg to 800 mg.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable amount of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) ranges from about 20 mg to 800 mg.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pharmaceutically acceptable amount of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) ranges from about 25 mg to 800 mg.

### Claim 8

A single-dose medicament, comprising, as an active ingredient, about 1 mg to 800 mg of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I):

### Claim 9 (depends on 8)

The single-dose medicament according to claim 8, wherein the single-dose medicament is used to treat and/or prevent an immune system disease.

### Claim 10 (depends on 9)

The single-dose medicament according to claim 9, wherein the immune system disease comprises an autoimmune disease and/or a skin allergy disorder.

### Claim 11 (depends on 9)

The single-dose medicament according to claim 9, wherein the immune system disease comprises rheumatoid arthritis, urticaria, skin inflammation, and/or eczema.

### Claim 12 (depends on 8)

The single-dose medicament according to claim 8, comprising, as the active ingredient, about 5 mg to 800 mg of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I).

### Claim 13 (depends on 8)

The single-dose medicament according to claim 8, comprising, as the active ingredient, about 10 mg to 800 mg of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I).

### Claim 14 (depends on 8)

The single-dose medicament according to claim 8, comprising, as the active ingredient, about 20 mg to 800 mg of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I).

### Claim 15 (depends on 8)

The single-dose medicament according to claim 8, comprising, as the active ingredient, about 25 mg to 800 mg of the compound represented by Formula (I), or the stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I).

### Claim 16 (depends on 8)

A method for treating and/or preventing an immune system disease, the method comprising:
administering to a subject a pharmaceutically acceptable dose of the single-dose medicament according to claim 8.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the immune system disease comprises an autoimmune disease and/or a skin allergy disorder.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the immune system disease comprises rheumatoid arthritis, urticaria, skin inflammation, and/or eczema.
